Results for imunomodulatora translation from Croatian to English

prestanak uzimanja kortikosteroida ili imunomodulatora i remisija fistula
discontinuation of corticosteroids or immunomodulators and fistula remission

stope prestanka uzimanja kortikosteroida ili imunomodulatora prikazane su u tablici 15.
rates of discontinuation of corticosteroids or immunomodulators are presented in table 15.

bile su dopuštene istovremene stabilne doze peroralnih kortikosteroida, imunomodulatora i antibiotika.
concomitant stable doses of oral corticosteroids, immunomodulators, and antibiotics were permitted.

bila je dopuštena istodobna primjena stabilnih doza peroralnih aminosalicilata i/ili imunomodulatora.
concomitant stable doses of oral aminosalicylates, and/or immunomodulatory agents were permitted.

bile su dopuštene istovremene stabilne doze oralnih aminosalicilata, kortikosteroida i/ili imunomodulatora.
concomitant stable doses of oral aminosalicylates, corticosteroids and/or immunomodulators were permitted.

dopuštala se istodobna primjena stabilnih doza peroralnih aminosalicilata, kortikosteroida i/ili imunomodulatora.
concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted.

bila je dopuštena istodobna primjena stabilnih doza peroralnih aminosalicilata, kortikosteroida i/ili imunomodulatora.
concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted.

istodobna primjena imunomodulatora povezana je s nižom incidencijom protutijela na infliksimab i smanjenom učestalošću reakcija na infuziju.
concomitant administration of immunomodulators has been associated with lower incidence of antibodies to infliximab and a reduction in the frequency of infusion reactions.

istodobna primjena imunomodulatora povezana je s nižom incidencijom protutijela na infliksimab i smanjenom učestalošću reakcija vezanih uz infuziju.
concomitant administration of immunomodulators has been associated with lower incidence of antibodies to infliximab and a reduction in the frequency of infusion reactions.

ima naznaka da istodobna primjena metotreksata i drugih imunomodulatora u bolesnika s reumatoidnim artritisom, psorijatičnim artritisom i crohnovom bolešću smanjuje stvaranje protutijela na infliksimab i povećava koncentraciju infliksimaba u plazmi.
in rheumatoid arthritis, psoriatic arthritis and crohn's disease patients, there are indications that concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies against infliximab and increases the plasma concentrations of infliximab.

u bolesnika s ulceroznim kolitisom liječenih golimumabom u supkutanoj dozi od 50 mg ili 100 mg svaka 4 tjedna, istodobna primjena imunomodulatora nije značajno utjecala na najniže koncentracije golimumaba u stanju dinamičke ravnoteže.
in uc patients treated with 50 mg or 100 mg golimumab subcutaneously every 4 weeks, concomitant use of immunomodulators did not have a substantial effect on steady-state trough levels of golimumab.

liječenje talidomidom mora započeti i pratiti liječnik s iskustvom u primjeni imunomodulatora ili kemoterapeutika koji u potpunosti shvaća rizike liječenja talidomidom i potrebu za nadzorom bolesnika (vidjeti dio 4.4).
thalidomide treatment must be initiated and monitored under the supervision of physicians with expertise in managing immunomodulatory or chemotherapeutic agents and a full understanding of the risks of thalidomide therapy and monitoring requirements (see section 4.4).

vedolizumab je ispitan u odraslih bolesnika s ulceroznim kolitisom i crohnovom bolešću uz istovremenu primjenu kortikosteroida, imunomodulatora (azatioprin, 6-merkaptopurin i metotreksat) te aminosalicilata.
vedolizumab has been studied in adult ulcerative colitis and crohn’s disease patients with concomitant administration of corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), and aminosalicylates.

eksplorativne analize podskupina iz kliničkih ispitivanja kod crohnove bolesti ukazuju da vedolizumab primijenjen u bolesnika bez istovremenog liječenja kortikosteroidima može biti manje djelotvoran u indukciji remisije crohnove bolesti nego u bolesnika koji već istovremeno uzimaju kortikosteroide (bez obzira na istovremeno uzimanje imunomodulatora; vidjeti dio 5.1).
exploratory subgroup analyses from the clinical trials in crohn’s disease suggested that vedolizumab administered in patients without concomitant corticosteroid treatment may be less effective for induction of remission in crohn’s disease than in those patients already receiving concomitant corticosteroids (regardless of use of concomitant immunomodulators; see section 5.1).